ENPP1 Affects Insulin Action and Secretion: Evidences from *In Vitro* Studies

Rosa Di Paola¹, Nunzia Caporarello², Antonella Marucci¹, Claudia Dimatteo¹, Claudia Iadicicco³, Silvia Del Guerra⁴, Sabrina Prudente⁵, Dora Sudano², Claudia Miele³, Cristina Parrino², Salvatore Piro⁶, Francesco Beguinot³, Piero Marchetti³, Vincenzo Trischitta¹,⁵,⁷, Lucia Frittitta²,⁴,⁷

¹ Research Unit of Diabetes and Endocrine Diseases, IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo, Italy, ² Unit of Endocrinology, Department of Clinical and Molecular Biomedicine, University of Catania Medical School, Garibaldi Hospital, Catania, Italy, ³ Dipartimento di Biologia e Patologia Cellulare e Molecolare and Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Università degli Studi di Napoli Federico II, Naples, Italy, ⁴ Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy, ⁵ IRCCS “Casa Sollievo della Sofferenza, Mendel Laboratory”, San Giovanni Rotondo, Italy, ⁶ Unit of Internal Medicine, Department of Clinical and Molecular Biomedicine, University of Catania Medical School, Garibaldi Hospital, Catania, Italy, ⁷ Department of Experimental Medicine, Sapienza University, Rome, Italy

Abstract

The aim of this study was to deepen the mechanisms through which ENPP1, a negative modulator of insulin receptor (IR) activation, plays a role on insulin signaling, insulin secretion and eventually glucose metabolism. ENPP1 cDNA (carrying either K121 or Q121 variant) was transfected in HepG2 liver-, L6 skeletal muscle- and INS1E beta-cells. Insulin-induced IR-autophosphorylation (HepG2, L6, INS1E), Akt-Ser⁴⁷³, ERK1/2-Thr⁰²¹/Tyr²⁰⁴ and GSK3-beta Ser⁹ phosphorylation (HepG2, L6), PEPCK mRNA levels (HepG2) and 2-deoxy-D-glucose uptake (L6) were studied. GLUT 4 mRNA (L6), insulin action and caspase-3 activation (INS1E) were also investigated. Insulin-induced IR-autophosphorylation was decreased in HepG2-K, L6-K, INS1E-K (20%, 52% and 11% reduction vs. untransfected cells) and twice as much in HepG2-Q, L6-Q, INS1E-Q (44%, 92% and 30%). Similar data were obtained with Akt-Ser⁴⁷³, ERK1/2-Thr²⁰²/Tyr²⁰⁴ and GSK3-beta Ser⁹ in HepG2 and L6. Insulin-induced reduction of PEPCK mRNA was progressively lower in untransfected HepG2-K and HepG2-Q cells (65%, 54%, 23%), insulin-induced glucose uptake in untreated L6 (60% increase over basal), was totally abolished in L6-K and L6-Q cells. GLUT 4 mRNA was slightly reduced in L6-K and twice as much in L6-Q (13% and 25% reduction vs. untransfected cells). Glucose-induced insulin secretion was 60% reduced in INS1E-K and almost abolished in INS1E-Q, Serum deficiency activated caspase-3 by two, three and four folds in untransfected INS1E, INS1E-K and INS1E-Q. Glyburide-induced insulin secretion was reduced by 50% in isolated human islets from homozygous QQ donors as compared to those from KK and KQ individuals. Our data clearly indicate that ENPP1, especially when the Q121 variant is operating, affects insulin signaling and glucose metabolism in skeletal muscle- and liver-cells and both function and survival of insulin secreting beta-cells, thus representing a strong pathogenic factor predisposing to insulin resistance, defective insulin secretion and glucose metabolism abnormalities.

Citation: Di Paola R, Caporarello N, Marucci A, Dimatteo C, Iadicicco C, et al. (2011) ENPP1 Affects Insulin Action and Secretion: Evidences from *In Vitro* Studies. PLoS ONE 6(5): e19462. doi:10.1371/journal.pone.0019462

Editor: Kathrin Maedler, University of Bremen, Germany

Received January 10, 2011; Accepted March 30, 2011; Published May 5, 2011

Copyright: © 2011 Di Paola et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by Italian Ministry of Health Grants: RC2008 RC2009 RC2010 (R.D.P.), RC2009 RC2011 (V.T.), RFO5ED01 (R.D.P.); Italian Ministry of University and Research Grant: RBNE01N429_009; Telethon Grants: E1239 (V.T.) and GGP02423 (R.D.P.); Fondazione Roma “Sostegno alla ricerca scientifica biomedica 2008” (V.T.); European Community’s PREPOBEDIA 201681 (F.B.) and FIRB RBIP0689BS (F.B.). The financial support of Telethon, Italy, to F.B. is also gratefully acknowledged. P.M. and S.D.G. are supported in part by the European Community, project IMIDIA, N. 115005. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: r.dipaola@operapadrepio.it (RDP); v.trischitta@operapadrepio.it (VT); lfrittita@unict.it (LF)

These authors contributed equally to this work.

Introduction

Type 2 diabetes mellitus is a complex disorders due to the combination of genetic and environmental factors. Impaired insulin action (i.e. insulin resistance) in liver and skeletal muscle as well as reduced pancreatic beta-cell insulin secretion are pathogenic for type 2 diabetes [1]. In the presence of insulin resistance, glucose homeostasis is preserved by compensatory hyperinsulinemia [2,3], with type 2 diabetes ensuing only when beta-cells fail to secrete sufficient insulin to adequately counteract impaired insulin sensitivity. Besides the established role of abnormal insulin signaling in predisposing to insulin resistance [4], studies in animal models have proposed that insulin signaling is essential also for beta-cell insulin secretion [5,6,7,8]. Along the same line of evidences, human non synonymous genetic variations which affect the insulin signaling pathway [9,10, 11,12] and which have been associated with *in vivo* insulin resistance [13,14], are also able to affect insulin secretion *in vivo* [13,15], in isolated human islets [8,16,17] and in cultured beta-cells [8,18]. Thus, an intriguing scenario has emerged suggesting that abnormalities impairing insulin signaling play a role on glucose homeostasis not only by affecting glucose metabolism in liver and skeletal muscle, but also by inducing defective insulin secretion [19,20].
Ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) is a class II transmembrane glycoprotein, which inhibits insulin receptor (IR) signaling and which has been, therefore, proposed as a candidate for insulin resistance [20,21]. In fact, in both cultured cells [22,23,24,25,26,27] and mice [28,29], increasing ENPP1 expression causes impaired insulin signaling and action. Moreover, ENPP1 is overexpressed in skeletal muscle, adipose tissue, fibroblasts and lymphocytes of insulin-resistant individuals [21,30,31,32,33]. Further support to the notion that ENPP1 may play a role on human insulin resistance derives from studies on the ENPP1 K121Q polymorphism [34], which has drawn some attention as a genetic determinant of human insulin resistance. Indeed, the Q121 variant has been associated with insulin resistance in several [35,36,37] although not all [38] large studies. Interestingly, it also predicts incident major cardiovascular events [39], an important clinical outcome of insulin resistance. These epidemiological associations have been proposed to be mediated by a stronger inhibitory activity on IR signaling, as compared to that exerted by the K121 variant [25,34,40]. However, such functional studies pointing to the K121Q polymorphism as a gain of function aminoacid substitution, have been obtained in non typical insulin target cells [25,34,40] and may not, therefore, be considered as conclusive. More recently, a deleterious effect of the Q121 variant on in vivo insulin secretion has been reported [37]. Whether this is given by a direct detrimental effect on beta-cells or, in contrast, it is secondary to alterations of the metabolic milieu related to whole body insulin resistance, is an additional open question, which deserves further studies to be answered.

The aim of this study was to deeper investigate in vitro the mechanisms through which ENPP1 plays a role on insulin signaling, insulin secretion and eventually glucose metabolism. To this purpose, the effect of ENPP1 expression (either the K121 or the Q121 variant) was investigated in the three most important cell types for maintenance of glucose homeostasis (i.e. liver-, skeletal muscle- and pancreatic beta-cells). In details, we studied i) insulin-induced IR activation in all three cell types, ii) downstream insulin signaling and subsequent insulin action on glucose metabolism in liver- and skeletal muscle-cells and iii) beta-cells insulin secretion and survival. The data we obtained clearly indicate that ENPP1, especially when the Q121 variant is operating, exerts a direct deleterious effect on all these cell types, thus representing a strong candidate as a pathogenic factor predisposing to insulin resistance, defective beta-cell insulin secretion and glucose metabolism abnormalities.

Results

Studies on IR autophosphorylation

IR tyrosine autophosphorylation was studied in human liver HepG2 cells, rat skeletal muscle L6 cells and rat pancreatic INS1E beta-cells. To this purpose, cells were transfected with either ENPP1-K121 (HepG2-K, L6-K and INS1E-K) or ENPP1-Q121 (HepG2-Q, L6-Q, and INS1E-Q) cDNA, and then stimulated with insulin as described in methods. Immunoblot analysis showed that insulin stimulation induced autophosphorylation of IR-beta subunit in HepG2 (Figure 1 A), L6 (Figure 1 B) and INS1E-neo (Figure 1 C) control cells. This effect was variably reduced in HepG2-K (20% reduction; Figure 1 A), L6-K (52% reduction; Figure 1 B) and INS1E-K (11% reduction; Figure 1 C). Such reduction was approximately doubled in HepG2-Q (44% reduction; Figure 1 A), L6-Q (92% reduction; Figure 1 B) and INS1E-Q cells (30% reduction; Figure 1 C).

These data, strongly suggest that ENPP1 is an inhibitor of IR autophosphorylation in typical insulin target cells, as well as in

Figure 1. Studies on IR autophosphorylation in HepG2 (A), L6 (B) and INS1E (C) cells. Cells were either transfected, or not, with ENPP1-K121 cDNA or with ENPP1-Q121 cDNA and then stimulated with insulin as described in methods. Equal amount of protein from cell lysates was immunoprecipitated with anti-PY antibody, separated by SDS-PAGE and probed with IR-beta subunit antibody. Bars (upper panels) represent quantitative analysis of IR autophosphorylation calculated as percentage of that of stimulated untransfected cells in each experiment (mean ± SEM), while representative immunoblots from the same experiment are shown in lower panels. (A) In HepG2 cells, insulin induced IR-beta subunit autophosphorylation. This effect was significantly reduced in HepG2-K (p<0.02, fourth vs. second bar, n = 3 experiments in separate times) and more profoundly in HepG2-Q (p<0.001, sixth vs. second bar, n = 3 experiments in separate times) cells. When properly tested, a progressive reduction was observed from control to HepG2-K and then HepG2-Q cells (p for trend<0.001). (B) In L6 cells, insulin induced IR-beta autophosphorylation. As compared to control cells, insulin effect was significantly reduced in L6-K (p=0.01, fourth vs. second bar, n = 3 experiments in separate times) and more profoundly in L6-Q cells (p<0.001, sixth vs. second bar, n = 3 experiments in separate times). When properly tested, a progressive reduction was observed from control to L6-K and then L6-Q cells (p for trend<0.001). (C) In INS1E cells, insulin induced IR-beta autophosphorylation. As compared to control cells, insulin effect was only slightly and not significantly reduced in INS1E-K (fourth vs. second bar, n = 3 experiments in separate times) and significantly reduced in INS1E-Q cells (30% reduction p=0.02, sixth vs. second bar, n = 3 experiments in separate times). When properly tested, a progressive reduction was observed from INS1E-neo to INS1E-K and then INS1E-Q cells (p for trend=0.024).

doi:10.1371/journal.pone.0019462.g001
insulin secreting beta-cells and that the Q121 variant is a gain of function aminoacid substitution with increased inhibitory activity.

Studies in non insulin target cells have suggested that ENPP1 inhibitory activity on IR autophosphorylation is mediated by ENPP1/IR interaction [24,25]. Given our present data, we sought to replicate this finding also in typical insulin target cells, as is the case of HepG2. Upon insulin stimulation, as compared to control cells, the amount of ENPP1 associated with IR (Figure 2) was increased by 54 fold in HepG2-K and by 97 fold in HepG2-Q cells. This confirms that also in liver cells ENPP1 inhibitory function on IR autophosphorylation is paralleled by ENPP1/IR interaction.

Studies on insulin signaling in HepG2 and L6 cells

In order to characterize the effect of ENPP1 on downstream insulin signaling in typical insulin target cells, we investigated Akt-Ser177, GSK3-beta Ser9 and ERK1/2 Thr202/Tyr204 insulin-induced phosphorylation in HepG2 and L6 cells (Supporting Information S1). Briefly, transfection of ENPP1-K121 cDNA in both HepG2 and L6 cells was able to significantly reduce insulin-induced Akt-Ser177, GSK3-beta Ser9, and ERK1/2 Thr202/Tyr204 phosphorylation (Figures S2, S3, S4). In cells transfected with ENPP1-Q121 cDNA, this inhibitory effect was magnified in most of these steps (Supporting Information S1 and Figures S2, S3, S4). The general picture that can be drawn from these data strongly suggests that the greater inhibitory effect on IR autophosphorylation exerted by the Q121 variant is retained at most downstream post receptor steps, thus resulting in a more profound inhibition of the entire insulin signaling pathway in both cell types.

Studies on insulin action in HepG2 and L6 cells

Insulin action on glucose metabolism was then assessed by studying mRNA level of the gluconeogenetic enzyme PEPCK in HepG2 cells and by investigating glucose transport and GLUT4 expression level in L6 cells. PEPCK mRNA level was reduced by 65% upon insulin stimulation in untransfected HepG2 control cells. This reduction was progressively smaller in HepG2-K (54% reduction, p = 0.03 vs. reduction in control cells, n = 3) and in HepG2-Q cells (23% reduction, p = 0.009 vs. reduction in control cells, n = 3). Insulin stimulation induced a 60% increase of glucose uptake in untransfected L6 control cells. In contrast, insulin effect on glucose transport was totally abolished in L6-K (n = 3) and L6-Q cells (n = 3). Of note, as compared to control cells, GLUT4 mRNA level was slightly and not significantly reduced in L6-K (13% reduction, p = 0.22, n = 3) and significantly decreased in L6-Q cells (25% reduction, p = 0.01, n = 3). Similarly, when GLUT1 mRNA level was measured, no difference at all was observed in L6-K (n = 3), while a significant reduction was observed in L6-Q (26% reduction, p = 0.05, n = 3) as compared to control cells.

Figures 2. ENPP1/IR interaction. Lower panel: HepG2 cells were either transfected (lanes 2–3) or not (lane 1) with ENPP1-K121 cDNA (lane 2) or with ENPP1-Q121 cDNA (lane 3) and stimulated with insulin as described in methods. Total cell lysates were immunoprecipitated by using anti IR-alpha subunit antibody and ENPP1/IR interaction was evaluated by Western blot analysis with anti-ENPP1 specific antibody. Bars (upper panel) represent quantitative analysis of three independent Western blots (mean ± SEM), while a representative experiment is shown in the lower panel. As compared to HepG2 control cells, the amount of ENPP1 associated with IR was greatly increased in HepG2-K (p < 0.002, second vs. first bars, n = 3 experiments in separate times) and even more profoundly in HepG2-Q (p < 0.001, third vs. first bars, n = 3 experiments in separate times) cells. When properly tested, a progressive increase of ENPP1/IR interaction was observed from control to HepG2-K and then HepG2-Q cells (p for trend < 0.001). doi:10.1371/journal.pone.0019462.g002

Discussion

An important finding of this study is that increasing ENPP1 expression in liver HepG2 and skeletal muscle L6 cells affects IR activation, downstream insulin signaling and insulin action on glucose metabolism. In both cell types, the relatively rare ENPP1 Q121 variant exhibits, as compared to the K121 variant, a greater inhibition of IR activation and of most subsequent insulin signaling and action steps, thus behaving as a gain of function aminoacid substitution. In HepG2 cells, the Q121 variant shows a stronger physical interaction with the IR. This strengthen the hypothesis emerged from previous studies carried out in non typical insulin target cells that, as compared to ENPP1 K121, the Q121 variant is a stronger inhibitor of insulin signaling and action because of a stronger protein-protein interaction with the IR [25].

An additional finding of this study, which is entirely novel, is that ENPP1 expression induces defective IR activation, reduced insulin secretion upon stimulation of both glucose and glyburide.
and increased susceptibility to apoptosis in pancreatic beta-cells; also in most of these circumstances, the Q121 variant behaves as a gain of function aminoacid substitution. Although not conclusive because too sparse, also data in isolated human islets are in line with an inhibitory effect of the Q121 variant on insulin secretion, at least when present in the homozygous state.

Taken altogether, these findings clearly indicate that ENPP1, especially when the Q121 variant is operating, affects in vitro the most important tissues controlling glucose metabolism, including liver, skeletal muscle and insulin secreting beta-cells. A deleterious effect of ENPP1 on IR signaling and insulin action has been recently reported also in rat 3T3L-1 adipocytes [26], thus providing evidences for a role of ENPP1 in another very important insulin target tissue. These data in insulin target cells are fully compatible with those obtained in genetically modified animals in which changes in ENPP1 expression was directly correlated with deterioration of insulin sensitivity and abnormal glucose homeostasis [28,29,41].

As far as data on glucose- as well as glyburide-stimulated insulin secretion is concerned, our findings contribute to support an emerging scenario suggesting that IR signaling abnormalities have a direct, detrimental role on insulin secreting beta-cells [5,6,7,19].

Figure 3. Studies on glucose-induced (A) and glyburide-induced (B) insulin secretion in INS1E cells. As compared to that of INS1E-neo control cells, glucose-induced insulin secretion (A) was markedly reduced in INS1E-K cells (p<0.005, n=5 experiments in separate times) and almost completely abolished in INS1E-Q cells (p<0.0001, n=5 experiments in separate times). Data are expressed as percentage of maximal secretion showed in INS1E-neo cells (mean ± SEM), which for glucose stimulation is obtained at 16.6 mM. When properly tested, a progressive reduction was observed from INS1E-neo to INS1E-K and then INS1E-Q cells (p for trend<0.001). As compared to that of INS1E-neo control cells, glyburide-induced insulin secretion (B) was almost completely abolished in both in INS1E-K and INS1E-Q cells (*p<0.0001 for both, n=3 experiments in separate times). Data are expressed as percentage of glyburide-induced insulin secretion in INS1E-neo cells (mean ± SEM).

doi:10.1371/journal.pone.0019462.g003
In this context, our present data are perfectly coherent with those reporting that other naturally occurring amino acid substitutions affecting insulin signaling, including IRS1 G972R [15,17] and TRIB3 Q84R, directly affects insulin secreting beta-cells [8,16]. The mechanism through which ENPP1 affects insulin secretion has not been addressed in this study. In beta-cells it has been reported that insulin signaling, through the activation of IRS1, PI3K [5,42] and Akt-2 [43], increases Ca\(^{2+}\) influx, especially from the endoplasmic reticulum and, therefore, facilitates insulin-containing granules trafficking and exocytosis. So, although entirely speculative, it can be hypothesized that, in cells over-expressing ENPP1, reduced insulin signaling causes defective intracellular Ca\(^{2+}\) availability and eventually reduced glucose- and glyburide-stimulated insulin secretion.

As far as our present data on the Q121 variant is concerned, it is of note they are quite consistent with previous findings obtained in vivo. As a matter of fact, several [35,36,37] although not all [38] large studies have reported that individuals carrying the Q121 variant are insulin resistant as compared to KK subjects and that those carrying the QQ genotype also show defective insulin secretion [37]. Despite so many in vitro and in vivo findings coherently reported by several groups, the most updated meta-analysis, involving a huge number of individuals shows that a perfect proxy of the ENPP1 Q121 variant is not an established (i.e. at genome-wide level of statistical significance) marker of type 2 diabetes [44]. Several factors, intrinsic to study designs and data analyses of most GWAS (recently reviewed in [20]), might explain, at least partly, this apparent discrepancy. Nonetheless, the lack of established association with type 2 diabetes leaves uncertain the role of the Q121 variant on glucose homeostasis.

Materials and Methods

Cell Lines

HepG2 cells (ATCC, Manassas, USA) were maintained at 37°C and 5% CO\(_2\) in DMEM/F12 containing 10% FBS. L6 (ATCC, Manassas, USA) were maintained in DMEM containing 25 mM glucose with 10% FBS. Rat insulin-secreting INS1E cells (a kind gift from C. B. Wollheim, Department of Cell Physiology and Metabolism, University of Geneva, Geneva, Switzerland) were grown at 37°C and 5% CO\(_2\), in RPMI 1640 medium containing 2 mM L-glutamine supplemented with 10% heat-inactivated FBS.

Plasmid

Full-length cDNA of ENPP1-K121 was kindly provided by Dr. I.D. Goldfine (San Francisco, University of California, USA) and
the full-length cDNA of ENPP1-Q121 was generated by site directed mutagenesis as previously described [45]. Both cDNAs were cloned in mammalian expression vector pRK7.

Transfections

HepG2 and L6 cells were transiently transfected with the full length cDNA of either ENPP1-K121 (HepG2-K and L6-K, respectively) or ENPP1-Q121 (HepG2-Q and L6-Q, respectively) by using TransIT reagent according to the manufacturers’ instruction (Mirus), and then starved overnight in DMEM containing either 0.5% FBS or 0.25% BSA before experiments. ENPP1 protein expression in each condition was evaluated by Western blot analysis (Figure S1 A and S1 B). INS1E cells were either transfected with a plasmid (pRK7-neo) containing the neomycin resistance gene (INS1E-neo), or with the pRK7-neo plus the ENPP1-K121 cDNA (INS1E-K) or with the pRK7-neo plus ENPP1-Q121 cDNA (INS1E-Q) by using the Fugene Transfection Reagent (Roche, Germany) according to the company’s instructions. Clones expressing a similar amount of ENPP1 were selected (Figure S1 C).

Western blot

Cells lysates were separated by SDS-PAGE and transferred to nitrocellulose membrane (Amersham Pharmacia Biotech). Blots were probed with specific antibodies HRP-conjugated anti-goat, anti-mouse and anti-rabbit antibodies (Santa Cruz Biotechnology) and the chemiluminescent substrate (Super Signaling West Pico Chemiluminescent Substrate, Thermo Scientific, Rockford, USA). Data were calculated as percentage of unstimulated untransfected HepG2 cells and expressed as means ± SEM.

2-Deoxy-D-glucose uptake in L6

2-Deoxy-D-glucose uptake in L6, L6-K and L6-Q cells was measured as previously reported [47]. Data were calculated as percentage over unstimulated cells and expressed as means ± SEM.

IR phosphorylation

HepG2, HepG2-K, HepG2-Q cells, L6, L6-K and L6-Q cells and INS1E-neo, INS1E-K and INS1E-Q cells were stimulated with 10^{-6} M insulin for 5 minutes at 37°C. Following cell lysis equal amount of protein was immunoprecipitated with anti-PY antibody (4G10 Platinum, Millipore, Italy), and analyzed by Western blot with anti IR-beta subunit antibody (C19, Santa Cruz Biotechnology, CA). IR phosphorylation was calculated as percentage of stimulated untransfected cells and expressed as means ± SEM.

ENPP1/IR interaction

Following insulin stimulation (10^{-6} M for 5 minutes) and cell lysis, 2 mg of proteins were immunoprecipitated with anti IR alpha-subunit antibody and analyzed by Western blot analysis by using ENPP1 specific polyclonal antibody (N20 Santa Cruz Biotechnology, CA). Data were calculated as percentage of stimulated untransfected cells and expressed as means ± SEM.

Insulin downstream signaling

Following insulin stimulation (10^{-6} M for 5–10 minutes) and cell lysis, equal amount of protein was analyzed by western blot with the following specific antibodies: phospho-Akt Ser473, phospho-ERK1/2 Thr202/Tyr204, phospho-GSK3 beta Ser9 (Cell Signaling, Boston, MA). The blot were then stripped and re-probed with antibodies against Akt, ERK1/2 and GSK3 beta for normalization (Cell Signaling, Boston, MA). Data were calculated as percentage of stimulated untransfected cells and expressed as means ± SEM.

PEPCK mRNA level

Thirty hours after transfection HepG2, HepG2-K and HepG2-Q cells were starved for 18 hours and then stimulated with 10^{-8} M insulin for 10 hours. Total RNA extraction and cDNA synthesis were performed as previously described [45]. PEPCK mRNA level was measured by RT-PCR by using the following primers: 5’-ATGTATGTCATTCCATGACG- 3’ and 5’-AATGTCATCACCACACATTGC-3’ [46]. Data were calculated as percentage of unstimulated untransfected HepG2 cells and expressed as means ± SEM.

GLUT 4 and GLUT 1 mRNA level

Total RNA from L6, L6-K and L6-Q cells was extracted and cDNA was obtained as previously described [45]. GLUT 4 and GLUT 1 mRNA level was measured by RT-PCR by using the following primers: 5’-CAGAAAGTGATTGAACAGAG-3’ and 5’-CAGCCGATGTTGACGAGAC-3’, 5’-GACGATACCGAGCGCCATG-3’ respectively [48]. Data were calculated as percentage of untransfected L6 cells and expressed as means ± SEM.

Insulin secretion in INS1E cells

Insulin secretion was evaluated as previously described [49]. Briefly, INS1E-neo, INS1E-K and INS1E-Q cells were seeded in six-well plates at a density of 8×10^5 cells/well and, after 24 hours, the medium was removed and cells washed twice with glucose-free Krebs solution (pH 7.4). After a 60 minute preincubation period (37°C, 5% CO_2) in Krebs solution containing 2.7 mM glucose, insulin secretion was determined in presence of increasing glucose concentrations (2.7; 5.5; 11.1; 16.6 and 22.2 mM) or 100 μM glyburide, a concentration used in previous in vitro studies [50]. After 60 minutes at 37°C, 5% CO_2, aliquots of supernatant were taken for the measurement of insulin secretion (Rat/Mouse Insulin ELISA Kit, Billerica, MA, U.S.A.), while total protein content was determined using BCA protein Assay (Thermo Scientific, Rockford, USA). Data were expressed as percentage of maximal secretion showed in INS1E-neo cells, which for glucose stimulation was obtained at 16.6 mM.

Apoptosis assay

For caspase-3 experiments, INS1E-neo, INS1E-K and INS1E-Q cells were cultured in RPMI or starved overnight in serum-free RPMI containing 1.1 mM glucose and 0.1% BSA. After cells lysis, equal amount of protein was analyzed by Western blot, using cleaved caspase 3 (asp 175) antibody (Cell Signaling, Boston, MA, USA). Data were calculated as percentage of untreated INS1E-neo cells (% of basal) and expressed as means ± SEM.

Pancreas donors

Pancreata were collected from 85 non diabetic brain-dead multiorgan donors (58±16 years 49.4% females) after informed consent was obtained in writing from family members, as previously reported [51]. The islet isolation centre has permission to prepare isolated islets and to use them for scientific research if they are not suitable for clinical islet transplantation, in accordance with national laws and our institutional ethical rules.
Human islet preparation
Pancreatic islets were prepared by collagenase digestion and density gradient purification, as previously reported in detail. After isolation, islets were cultured in M-199 culture medium as previously described [52].

DNA extraction
DNA was extracted from batches of 2000 isolated islets in according to the Wizard genomic DNA purification protocol (Promega, Madison, WI, USA). Total DNA was quantified by absorbance at A260/A280 nm (ratio > 1.65) in a Perkin-Elmer spectrophotometer, and its integrity assessed by electrophoresis on 1.0% agarose gel by ethidium bromide staining.

Insulin secretion in isolated human islets
Insulin secretion was determined as previously described [52]. Briefly, following a 45 minute preincubation period at 3.3 mM glucose, batches of 15 islets of comparable size were kept at 37°C for 45 minutes in Krebs-Ringer bicarbonate solution (KRB) and 0.5% albumin, pH 7.4, containing 3.3 mM glucose. At the end of this period, the medium was completely removed and replaced with KRB containing 16.7 mM glucose and 3.3 mM G plus 100 μM glyburide [53,54]. After an additional 45 minute of incubation, the medium was removed and stored at -20°C until insulin concentrations were measured by immunoradiometric assay (Pantec Forniture Biomediche, Turin, Italy). Data are expressed as stimulation index calculated by dividing stimulated insulin release (either by glucose 16.7 mM or by glyburide 10 μM) over basal insulin release (at glucose 3.3 mM).

Genotyping of isolated human islets
Polymorphism K121Q (rs1044498) at ENPP1 locus was genotyped by TaqMan allele discrimination (assay C_16190162_10, Applied Biosystems, Forster City, CA) on the HT7900 platform (Applied Biosystems). The failure rate was <1%. Genotyping quality was assessed by including positive controls with known genotypes. The agreement rate was ≥99%. Genotype distribution in the study sample was in Hardy-Weinberg equilibrium.

Genotyping of isolated human islets
Polymorphism K121Q (rs1044498) at ENPP1 locus was genotyped by TaqMan allele discrimination (assay C_16190162_10, Applied Biosystems, Forster City, CA) on the HT7900 platform (Applied Biosystems). The failure rate was <1%. Genotyping quality was assessed by including positive controls with known genotypes. The agreement rate was ≥99%. Genotype distribution in the study sample was in Hardy-Weinberg equilibrium.

Statistical analysis
Differences between mean values were evaluated by unpaired or paired Student’s t test, as appropriate. General linear model was used to test the hypothesis that insulin signaling, action and secretion was progressively worse from control cells to K-cells and then Q-cells.

Supporting Information
Figure S1 ENPP1 expression in HepG2, L6 and INS1E cells. HepG2 and L6 cells (A, B) were transiently transfected with the full length cDNAs of either ENPP1-K121 (HepG2-K and L6-K, respectively) or ENPP1-Q121 (HepG2-Q and L6-Q, respectively). ENPP1 protein content was then evaluated by Western blot analysis with specific antibody. Representative experiments are shown. INS1E cells (C) were stably transfected as described in methods. Two cell clones were isolated after transfection with a plasmid (pRK-7-neo) containing the neomycin resistance gene and co-transfected with ENPP1-K121 cDNA (INS1E-K, lane 3) or with ENPP1-Q121 cDNA (INS1E-Q, lane 4). Two clones expressing a similar amount of ENPP1 were selected. Three different experiments were carried out and a representative experiment is shown.

Figure S2 Studies on Akt-S473 phosphorylation in HepG2 and L6 cells. Cells were either transfected or not with ENPP1-K121 cDNA or with ENPP1-Q121 cDNA and stimulated with insulin as described in methods. Equal amount of protein from cell lysates was separated by SDS-PAGE and Akt-S473 phosphorylation was evaluated by using specific antibody by Western blot analysis. To evaluate Akt protein content, blots were stripped and reprobed with specific antibody. Bars (upper panels) represent quantitative analysis of Akt-S473 phosphorylation calculated in each single experiment as percentage of that of insulin stimulated untransfected cells (mean ± SEM), while representative immunoblots from the same experiment are shown in the lower panels. In HepG2 cells (A), insulin strongly stimulated Akt-S473 phosphorylation. As compared to control cells, insulin effect was significantly and similarly reduced in both HepG2-K and HepG2-Q cells (*p<0.005, both fourth and sixth vs. second bar, n = 3 experiments in separate times). In L6 cells (B), insulin strongly induced Akt-S473 phosphorylation. As compared to control cells, insulin effect was significantly reduced in both L6-K (p = 0.02, fourth vs. second bar, n = 3 experiments in separate times) and L6-Q cells (p<0.001, sixth vs. second bar, n = 3 experiments in separate times). When properly tested, a progressive reduction was observed from control to L6-K and then L6-Q cells (p for trend<0.001).

Figure S3 Studies on GSK3-beta S9 phosphorylation in HepG2 and L6 cells. Cells were either transfected or not with ENPP1-K121 cDNA or with ENPP1-Q121 cDNA and stimulated with insulin as described in methods. Equal amount of protein from cell lysates were separated by SDS-PAGE and GSK3-beta S9 phosphorylation was evaluated by using specific antibody by Western blot analysis. GSK3-beta protein content was evaluated by stripping and reprobing the same blot with specific antibody. Bars (upper panels) represent quantitative analysis of GSK3-beta S9 phosphorylation calculated in each single experiment as percentage of that of insulin stimulated untransfected cells (mean ± SEM), while representative immunoblots from the same experiment are shown in the lower panels. In HepG2 cells (A), insulin greatly induced GSK3-beta S9 phosphorylation. As compared to control cells, this effect was reduced in HepG2-K (p = 0.02, fourth vs. second bar, n = 3 experiments in separate times) and more strongly in HepG2-Q cells (p<0.001, sixth vs. second bar, n = 3 experiments in separate times). When properly tested, a progressive reduction was observed from control to HepG2-K and then HepG2-Q cells (p for trend = 0.002). In L6 cells (B), insulin induced GSK3-beta S9 phosphorylation. As compared to control cells, this effect was similarly reduced in L6-K (p = 0.003, fourth vs. second bar, n = 3 experiments in separate times) and in L6-Q cells (p<0.001, sixth vs. second bar, n = 3 experiments in separate times). When properly tested, a progressive reduction was observed from control to L6-K and then L6-Q cells (p for trend = 0.003).

Figure S4 Studies on ERK1/2 Thr202/Tyr204 phosphorylation in HepG2 and L6 cells. Cells were either transfected or not with ENPP1-K121 cDNA or with ENPP1-Q121 cDNA and stimulated with insulin as described in methods. Equal amount of protein from cell lysates was separated by SDS-PAGE and ERK1/2 Thr202/Tyr204 phosphorylation was evaluated by using specific antibody by Western blot analysis. ERK1/2 protein content was...
evaluated by stripping and reprobing the same blot with specific antibody. Bars (upper panels) represent quantitative analysis of ERK1/2 Thr202/Tyr204 phosphorylation calculated in each single experiment as percentage of that of insulin stimulated untransfected cells (mean ± SEM), while representative immunoblots from the same blot are shown in the lower panels. In HepG2 cells (A), insulin induced ERK1/2 activation. As compared to control cells, insulin effect was significantly reduced in both HepG2-K (p = 0.003, fourth vs. second bar, n = 3 experiments in separate times) and slightly more HepG2-Q cells (p < 0.001, sixth vs. second bar, n = 3 experiments in separate times). When properly tested, a progressive reduction was observed from control to L6-K and then L6-Q cells (p for trend < 0.001).

(TIF)

Supporting Information S1 Studies on insulin signaling in HepG2 and L6 cells.

(DOC)

Author Contributions

Conceived and designed the experiments: RDP NC AM CD CI SDG DS.

Performed the experiments: NC AM CD SI DG S F.

Analyzed the data: RDP CM PM VT LF.

Contributed reagents/materials/analysis tools: RDP FB.

Wrote the paper: RDP VT.

References

1. DeFronzo RA (1986) Lilly lecture 1986. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM and cardiovascular risk. Nat Rev Endocrinol. 5: 667-687.

2. Warram JH, Martin RG, Krolofspin AS, Soeldner JS, Kahn CR (1990) Slow slow-pancreatic beta cells. J Clin Invest 104: 357–364.

3. Lillioja S, Mott DM, Spira J, Ferraro R, Foley JE, et al. (1993) Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329: 1908-1992.

4. Virkamaki A, Ueki K, Kahn CR (1999) Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103: 931–943.

5. Kulkarni RN, Brining JC, Winnay JN, Kawamori D, Hu J, Leech CA, et al. (2004) Insulin exocytosis in human and mouse beta cells. J Clin Invest 120: 2876–2888.

6. Liang J, Fu M, Ciociola E, Chandalia M, Abate N (2007) TRIB3 R84 variant is associated with impaired insulin-mediated nitric oxide production in vivo and in vitro insulin action in nondiabetic subjects: evidence that PC-1 may be an intrinsic factor in impaired insulin receptor signaling. Diabetes 56: 2807-2811.

7. Androzzi F, Formoso G, Prudente S, Hribal ML, Pandolfi A, et al. (2008) TRIB3 R14 variant is associated with impaired muscle-nitric oxide production in human endothelial cells. Arterioscler Thromb Vasc Biol 28: 1355-1360.

8. Prudente S, Baratta R, Androzzi F, Morini E, Farina MG, et al. (2010) TRIB3 R14 variant affects glucose homeostasis by altering the interplay between insulin sensitivity and secretion. Diabetologia 53: 1354-1361.

9. Claassen JG, Rump DJ, Bjerregaard C, Echwald SM, Ummaker SA, et al. (1995) Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. Lancet 346: 397–402.

10. Stumvoll M, Frische A, Volk A, Stefan N, Malaus A, et al. (2001) The Gly to Arg substitution in the insulin receptor substrate-1 gene contributes to variation in insulin secretion in normal glucose tolerant humans. Diabetes 50: 397–402.

11. Prudente S, Baratta R, Androzzi F, Morini E, Farina MG, et al. (2010) The TRIB3 R14 variant is associated with impaired muscle-nitric oxide production in human endothelial cells. Arterioscler Thromb Vasc Biol 28: 1355-1360.

12. Prudente S, Baratta R, Androzzi F, Morini E, Farina MG, et al. (2010) TRIB3 R14 variant affects glucose homeostasis by altering the interplay between insulin sensitivity and secretion. Diabetologia 53: 1354-1361.

13. Liew CW, Bochenski J, Kawamori D, Hu J, Leech CA, et al. (2010) The Q allele variant of membrane glycoprotein PC-1 interacts with the insulin receptor and inhibits insulin signaling more effectively than the common K allele variant (L5121). Diabetes 59: 831–836.

14. Belloir A, Costantino A, Frasca F, Pandini G, Minoia R, et al. (1996) The Q allele variant of membrane glycoprotein PC-1 in a MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity. Mol Endocrinol 10: 1318-1326.

15. Maddux BA, Goldfine ID (2000) Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit. Diabetes 49: 13-19.

16. Prudente S, Chandalia M, Zhang YY, Morini E, et al. (2009) The Q allele variant (GLN121) of membrane glycoprotein PC-1 interacts with the insulin receptor and inhibits insulin signaling more effectively than the common K allele variant (L5121). Diabetes 58: 397–402.

17. Lee CW, Bochinski J, Kawamori D, Hu J, Leech CA, et al. (2010) The pseudokinase triibbles homolog 3 interacts with ATF4 to negatively regulate insulin exocytosis in human and mouse beta cells. J Clin Invest 120: 2876–2888.

18. Almind K, Iose G, Pedersen O, Kahn CR (1996) A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 95: 2569–2575.

19. Hribal ML, Federici M, Porzio O, Lauro D, Borboni P, et al. (2000) The Gly to Arg substitution in the insulin receptor substrate-1 gene affects glucose metabolism in skeletal muscle cells. J Clin Endocrinol Metab 85: 2004–2013.

20. Prudente S, Hribal ML, Flex E, Turchi F, Morini E, et al. (2005) The functional Q to R substitution in mammalian Triubles homolog TRIB3 is associated with insulin resistance and a related cardiovascular risk in Caucasians from Italy. Diabetologia 54: 2807–2811.

21. Prudente S, Baratta R, Androzzi F, Morini E, Farina MG, et al. (2010) TRIB3 R14 variant is associated with impaired muscle-nitric oxide production in human endothelial cells. Arterioscler Thromb Vasc Biol 28: 1355-1360.

22. Prudente S, Baratta R, Androzzi F, Morini E, Farina MG, et al. (2010) TRIB3 R14 variant affects glucose homeostasis by altering the interplay between insulin sensitivity and secretion. Diabetologia 53: 1354-1361.

23. Lillioja S, Mott DM, Spira J, Ferraro R, Foley JE, et al. (1993) Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329: 1908-1992.

24. Liew CW, Bochinski J, Kawamori D, Hu J, Leech CA, et al. (2010) The pseudokinase triibbles homolog 3 interacts with ATF4 to negatively regulate insulin exocytosis in human and mouse beta cells. J Clin Invest 120: 2876–2888.

25. Almind K, Iose G, Pedersen O, Kahn CR (1996) A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 95: 2569–2575.

26. Liang J, Fu M, Ciociola E, Chandalia M, Abate N (2007) TRIB3 R84 variant is associated with impaired insulin-mediated nitric oxide production in vivo and in vitro insulin action in nondiabetic subjects: evidence that PC-1 may be an intrinsic factor in impaired insulin receptor signaling. Diabetes 56: 1195–1199.

27. Stoz FF, Katabi AE (2007) Transcription and protein expression changes involved in insulin resistance in muscle and activated T-lymphocytes of patients with type 2 diabetes. Genomics Proteomics Bioinformatics 5: 216-233.

28. Prudente S, Baratta R, Androzzi F, Morini E, Farina MG, et al. (2010) Elevated PC-1 content in cultured skin fibroblasts correlates with decreased in vivo and in vitro insulin action in nondiabetic subjects: evidence that PC-1 may be an intrinsic factor in impaired insulin receptor signaling. Diabetes 57: 1180–1186.

29. Teno S, Kanno H, Oga S, Sunakuma S, Kamamuro I, et al. (1999) Increased PC-1 alpha gene expression, is associated with a reduction of both whole body insulin sensitivity and insulin receptor tyrosine-kinase activity. Diabetes 50: 282–289.

30. Tost H, Maddux BA, Alzontante J, Meschke ML, Accili D, et al. (2005) Increased hepatic levels of the insulin receptor inhibitor, PC-1/PP1, induce insulin resistance and glucose intolerance. Diabetes 54: 367–372.

31. Maddux BA, Goldfine ID (2000) Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit. Diabetes 49: 13-19.

32. Prudente S, Chandalia M, Zhang YY, Morini E, et al. (2009) The Q allele variant (GLN121) of membrane glycoprotein PC-1 interacts with the insulin receptor and inhibits insulin signaling more effectively than the common K allele variant (L5121). Diabetes 58: 397–402.

33. Prudente S, Chandalia M, Zhang YY, Morini E, et al. (2009) The Q allele variant (GLN121) of membrane glycoprotein PC-1 interacts with the insulin receptor and inhibits insulin signaling more effectively than the common K allele variant (L5121). Diabetes 58: 397–402.
38. Graup N, Urhammer SA, Albrechtsen A, Glumer C, et al. (2006) Studies of the relationship between the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 Danish white subjects. Diabetologia 49: 2097–2104.

39. Bacci S, Rizza S, Prudente S, Spoto B, Powers C, et al. (2011) The ENPP1 Q121 variant predicts major cardiovascular events in high-risk individuals: evidence for interaction with obesity in diabetic patients. Diabetes 60: 1000–1007.

40. Bacci S, Di Paola R, Menzaghi C, Di Fulvio P, Di Silvestre S, et al. (2009) ENPP1 Q121 variant, increased pulse pressure and reduced insulin signaling, and nitric oxide synthase activity in endothelial cells. Arterioscler Thromb Vasc Biol 29: 1678–1683.

41. Zhou HH, Chin CN, Wu M, Ni W, Quan S, et al. (2009) Suppression of PC-1/ENPP-1 expression improves insulin sensitivity in vitro and in vivo. Eur J Pharmacol 616: 346–352.

42. Aspinwall CA, Qian WJ, Roper MG, Kulkarni RN, Kahn CR, et al. (2000) Roles of insulin receptor substrate-1, phosphatidylinositol 3-kinase, and release of intracellular Ca2+ stores in insulin-stimulated insulin secretion in beta cells. J Biol Chem 275: 22331–22338.

43. Bernal-Mizrachi E, Fatrai S, Johnson JD, Ohsugi M, Otani K, et al. (2004) Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet beta cells. J Clin Invest 114: 928–936.

44. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, et al. (2010) Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 42: 579–589.

45. Marucci A, Miscio G, Padovano L, Boonyasrisawat W, Florez JC, et al. (2009) The role of HSP70 on ENPP1 expression and insulin-receptor activation. J Mol Med 87: 139–144.

46. Marchetti P, Bugliani M, Lupi R, Marselli L, Masini M, et al. (2007) The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia 50: 2486–2494.

47. Miele C, Riboselet A, Maitan MA, Oriente F, Romano C, et al. (2003) Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C alpha-mediated mechanism. J Biol Chem 278: 47376–47387.

48. Raciti GA, Iadicicco G, Ulianich L, Vinod BF, Gaster M, et al. (2010) Glucosamine-induced endoplasmic reticulum stress affects GLUT4 expression via activating transcription factor 6 in rat and human skeletal muscle cells. Diabetologia 53: 955–965.

49. Anello M, Spampinato D, Piro S, Purrello F, Rabuazzo AM (2004) Glucosamine-induced alterations of mitochondrial function in pancreatic B-cells: possible role of protein glycosylation. Am J Physiol Endocrinol Metab 287: E602–E608.

50. Parker JC, VanVolkenburg MA, Gao F (2004) Synergistic effect on insulin secretion from INS-1 cells of a sulfonylurea and a phosphodiesterase 3 inhibitor. Life Sci 75: 1479–1490.

51. Clare L, Kirkpatrick CL, Marchetti P, Perrelli F, Piro S, et al. (2010) Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human alpha and beta cells: correlations with age or BMI of islet donors. PLoS One 5: e11053.

52. Marchetti P, Baglioni M, Lupi R, Marselli L, Masini M, et al. (2007) The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia 50: 2486–2494.

53. Del Guerra S, Lupi R, Marselli L, Masini M, Baglioni M, et al. (2005) Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 54: 727–735

54. Maedler K, Carr KD, Bosco D, Zuelig RA, Berney T, et al. (2003) Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90: 501–506.